Merck receives patent for CRISPR tech in China
Merck KGaA (MRK.XE) said Monday that it has received a patent for its CRISPR genome-editing technology in China.
The CRISPR technology allows for precise chromosome modification in living cells, said Merck. Its applications range “from identifying genes linked to cancer and rare diseases to reversing mutations that cause blindness,” the company said.
Merck said that it will license CRISPR-related patents to interested parties.
The company has related patent filings in the U.S., Brazil, India and Japan. It also has had similar patents granted in Australia, Canada, Europe, Singapore and South Korea, it said.
Published at Mon, 23 Apr 2018 13:29:00 +0000